Company intelligence / Profile preview

Qingdao Growful Pharmaceutical

Ownership: Private
Employees: ~691
Development stage: Other

Overview

Qingdao Growful Pharmaceutical has several approved products: Xiaoer Feire Kechuan Granules, for bronchitis/common cold, approved in China since February 2020. Yinqiao Jiedu Granules, for common cold, approved in China since January 2020. Polysaccharide Iron Complex, for iron deficiency anemia, first approved in the United States on January 10, 2017. The company also markets YangXinShi for myocardial infarction. No recent clinical trial activity is reported beyond these approvals.

Therapeutic areas: NeurologyPulmonologyInfectious DiseasesHematologyCardiovascular
Modalities: Herbal medicineSmall molecule drugPolysaccharide iron complex
Industry: Biotech

Drug pipeline

6 assets

yangxinshi

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Qingdao Growful Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qingdao Growful Pharmaceutical.

Explore the full profile